Skip to main content

Articles

Payers' Guide, FDA Approvals

Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer

FDA Approvals, Payers' Guide

Once-Fatal Conditions Have Become Chronic: Early Trends in the FDA’s 2015 Approvals

Payers' Guide, FDA Approvals

Glyxambi (Empagliflozin/Linagliptin): A Dual- Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes

Payers' Guide, FDA Approvals

Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer

Payers' Guide, FDA Approvals

Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma

Mitigating the Burden of Type 2 Diabetes: Challenges and Opportunities

Interview with the Innovators

Unclear Diagnoses in Patients with Metastatic Disease

Interview with the Innovators

The bioT3 platform

Interview with the Innovators

Clinical Validation of CancerTYPE ID

Interview with the Innovators

CancerTYPE ID in the Clinic

Page 138 of 244
Results 1371 - 1380 of 2436